Join Jackie Hunter at the Endpoints London Biotech Summit for a discussion on ROI and Innovation in drug development: What are the big and little biopharmas doing to change the equation?
Jackie Hunter is currently a Board Director of BenevolentAI, a UK unicorn company that uses artificial intelligence to disrupt the drug discovery and development process.. She has held numerous senior leadership positions in the pharmaceutical, biotechnology and innovation industries industries, working for a number of companies including Smithkline Beecham, GSK, Proximagen and latterly OI Pharma Partners, which she founded in 2010. Jackie served as CEO of the Biotechnology and Biological Sciences Research Council between 2013 and 2016. She is also a Fellow of the British Pharmacological Society and of the Academy of Medical Sciences. For her services to the pharmaceutical industry, she was awarded a CBE in 2010 Birthday Honours and the 2010 Women of Achievement in Science, Engineering and Technology Award for Discovery, Innovation and Entrepreneurship. She is a member of the Biomedical Advisory Board member for A* Singapore and a non-Executive Director of the UK Bioindustry Association.